Physician profile
Peter Fay
NPI 1578564340
$1,531.26
in general payments reported to CMS, 2019-2025
11 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $19.40 · 2021: $99.37 · 2022: $165 · 2023: $541 · 2024: $196 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $415.15 | 2023-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $390.35 | 2022-2025 | |
| Alcon Vision LLC | $315.10 | 2019-2025 | Rocklatan, Rhopressa |
| New World Medical,INC. | $170.67 | 2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Rxsight INC | $86.66 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Lensar, INC. | $50.12 | 2019 | |
| Carl Zeiss Meditec, INC. | $36.00 | 2023 | Veracity Surgical |
| Novartis Pharmaceuticals Corporation | $20.17 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $14.13 | 2021 | |
| Sight Sciences, INC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Fay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.